Document vEwv34eqXmNEKkgknNRNvrRq

FW: Presentations from Munich Benzene Symposium From: "Cushman, Janette (JCushman)" <jcushman@chevron.com > To: "Jackson, Lucinda (LUAJ)" <lucindajackson@chevron.com> Cc: "Satin, Ken (KSAT)" <ksat@chevron.com>, "Stine, Eric (EStine)" <estine@chevron.com> Date: Thu, 01 Oct 2009 17:48:53 +0100 Attachments: WONG Munich presentation 2009-09-08.pdf (375.6 kB) Here is the presentation on the benzene case control study that was presented in Munich. As you can see, it is a very technical presentation that is being reviewed by Eric Stine and Ken Satin. - The first few slides talk about the design of the study. - Slides 26 & 27 have the odds ratios (OR) for the acute myeloid leukemia (AML), summary of the results on slides 29 & 30 - Slide 47 has a summary of the OR for follicular lymphoma (FL- 7.00) (which falls into the broad category of non-Hodgkin lymphoid neoplasms - NHLN), summary of the results on slide 48. - Limitations of the study are listed on slide 49 and conclusions on slide 50. Regards, Jan janette R. Cushman Manager, Toxicology & Health Risk Assessment Chevron Energy Technology Company 1450 Marina Way South Richmond, CA 94804 1-51 0-242-9349 From: Stine, Eric (EStine) Sent: Tuesday, September 29, 2009 9:48AM To: Cushman, Janette (JCushman) Subject: FW: Presentations from Munich Benzene Symposium As you requested, Otto Wong;s presentation is the first one attached, above. Richard !ron;s presentation is the second presentation; also interesting! dealing with disease progression and MDS. Eric From: Howard Feldman [mailto:Feldman@api.org] CGU BEN0000863 Sent: Friday, September 11, 2009 6:04 AM To: BHRC Communications Committee; BenzConsort-TC@Iistserve.api.org; BenzConsort-OC@Iistserve.api.org Cc: Kimberly Wise Subject: Presentations from Munich Benzene Symposium The Munich Benzene Symposium has now been completed. Subsequently, we have now solicited and received electronic versions of the presentations from several of the presenters. Thus far we have received presentations from Drs Otto Wong, Richard Irons, and Sherilyn Gross, which are attached. As additional presentations are received, we will forward them to the group. Reminder that the next call of the BHRC Oversight Committee will be September 24 starting at 4 PM. Howard J. Feldman Director Regulatory & Scientific Affairs 1220 L Street, NW Washington, DC 20005-4070 USA Telephone 202-682-8340 Fax 202-682-8270 E-mail feldman:'(ilcJpi org CGU BEN0000864